The growing appreciation that dysfunction of the blood–brain barrier and increased permeability of the brain vasculature contributes to neurological diseases, such as dementia and Alzheimer’s disease [33], suggests that anti-VEGF-based therapies will be used to manage a wider spectrum of diseases in the future. Here, VEGFA is linked to early-onset autosomal dominant Alzheimer disease.